ASCENDIS PHARMA A/S

(ASND)
  Report
Real-time Estimate Cboe BZX  -  10:05 2022-08-18 am EDT
95.40 USD   -1.44%
08/16European ADRs Nudge Lower in Tuesday Trading
MT
08/12ASCENDIS PHARMA A/S : Notice to convene Extraordinary General Meeting - Form 6-K
PU
08/11European ADRs Move Lower in Thursday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

European ADRs Move Lower in Friday Trading

06/03/2022 | 11:04am EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ADAPTIMMUNE THERAPEUTICS PLC 0.48% 2.09 Delayed Quote.-44.27%
AMARIN CORPORATION PLC -2.15% 1.595 Delayed Quote.-51.63%
ARGENX SE -0.93% 373.2 Real-time Quote.19.54%
ASCENDIS PHARMA A/S -1.23% 95.6 Delayed Quote.-28.05%
CARNIVAL CORPORATION -2.85% 10.2889 Delayed Quote.-47.51%
LLOYDS BANKING GROUP PLC -0.26% 45.68 Delayed Quote.-4.22%
MATERIALISE NV -1.80% 12.63 Delayed Quote.-46.46%
MEREO BIOPHARMA GROUP PLC -2.12% 1.1501 Delayed Quote.-26.25%
NATUZZI S.P.A. 1.52% 8 Delayed Quote.-50.53%
NUCANA PLC -2.56% 1.5785 Delayed Quote.-31.93%
OPERA LIMITED -2.30% 4.875 Delayed Quote.-29.32%
SPARK NETWORKS SE 4.39% 3.09 Delayed Quote.-5.73%
STMICROELECTRONICS N.V. 1.82% 36.57 Real-time Quote.-17.13%
TRINITY BIOTECH PLC -0.66% 1.39 Delayed Quote.-2.15%
TRIVAGO N.V. -2.06% 1.665 Delayed Quote.-22.02%
VERONA PHARMA PLC 2.50% 12.2527 Delayed Quote.79.02%
All news about ASCENDIS PHARMA A/S
08/16European ADRs Nudge Lower in Tuesday Trading
MT
08/12ASCENDIS PHARMA A/S : Notice to convene Extraordinary General Meeting - Form 6-K
PU
08/11European ADRs Move Lower in Thursday Trading
MT
08/11Morgan Stanley Cuts Price Target on Ascendis Pharma A/S to $148 From $152, Keeps Overwe..
MT
08/11Oppenheimer Adjusts Ascendis Pharma Price Target to $144 From $154, Maintains Outperfor..
MT
08/11SVB Financial Adjusts Ascendis Pharma Price Target to $168 From $174, Maintains Outperf..
MT
08/10ASCENDIS PHARMA A/S : Reports Second Quarter 2022 Financial Results - Form 6-K
PU
08/10TRANSCRIPT : Ascendis Pharma A/S, Q2 2022 Earnings Call, Aug 10, 2022
CI
08/10Ascendis Pharma Q2 Loss Shrinks as Revenue Rises
MT
08/10Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results
AQ
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
Financials
Sales 2022 35,0 M 35,6 M 35,6 M
Net income 2022 -497 M -505 M -505 M
Net cash 2022 687 M 699 M 699 M
P/E ratio 2022 -10,6x
Yield 2022 -
Capitalization 5 312 M 5 402 M 5 402 M
EV / Sales 2022 132x
EV / Sales 2023 35,7x
Nbr of Employees 639
Free-Float 10,3%
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 95,17 €
Average target price 141,08 €
Spread / Average Target 48,2%
EPS Revisions
Managers and Directors
Jan M°ller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Birgitte Volck SVP, Head-Clinical Development & Medical Affairs
Kennett Sprog°e Senior Vice President, Head-Innovation & Research
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S-28.05%5 402
GILEAD SCIENCES, INC.-9.08%82 747
VERTEX PHARMACEUTICALS37.98%76 740
REGENERON PHARMACEUTICALS, INC.0.76%68 030
WUXI APPTEC CO., LTD.-22.47%39 407
BIONTECH SE-41.02%36 949